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Abstract
This paper reviews the antibacterial potential of enzybiotics against Methicillin-resistant Staphylococcus aureus (MRSA). Due
to the increasing occurrence of antibiotic resistance, researchers are looking to make use of the natural antibacterial qualities
of virus bacteriophages, viral derived lysins, and antimicrobial peptides to fight MRSA infections. The efficacy of bacteriophages,
endolysins, and bacteriocins as potential antibacterial agents against MRSA was extensively researched through Touro’s online
library database. Each of their mechanisms of action allows them to effectively lyse S. aureus cells, by essentially disrupting the
peptidoglycan in the cell wall, causing it to burst.The narrow host range of these antimicrobials causes eradication of only pathogenic bacteria while maintaining the state of normal flora. Researchers have tested the ability of bacteriophages to effectively
eliminate MRSA and have experimentally created therapeutically effective phage cocktails to delay the development of bacterial
resistance. Different in-vitro and in-vivo studies demonstrate the ability of endolysins to rapidly kill S. aureus regardless of their
metabolic state. Truncated and chimeric endolysins are used to optimize certain endolysin properties while eliminating negative
ones. The therapeutic use of bacteriocins has significantly reduced and even completely eradicated MRSA infections in rabbit
and mice in-vivo studies. Additionally, bacteriocins display synergy when used along with endolysins. All areas of enzybiotics show
synergy with antibiotics when both treatments are combined. Additional research must be done before bacteriophages, endolysins,
and bacteriocins can be used as a new antibacterial agent against MRSA.
Introduction
One of the greatest medical discoveries was the discovery
of antibiotics in the 20th century, which caused the mortality rate of patients suffering from infectious diseases to
drop dramatically. Other methods of treating bacterial infections were available at that time but were discontinued
after the use of antibiotics became prominent. There are
two major disadvantages to the use of antibiotics, the first
being that aside from killing the unwanted bacteria they
also kill the beneficial ones. The second is antibiotic resistance. Antibiotic resistance occurs when bacteria evolve
mechanisms that protect themselves against the effects
of antibiotic drugs. With a major misuse of antibiotics
globally, antibiotic-resistant bacteria are quickly increasing
each year. The discovery of new classes of antibiotics has
been slow and is not keeping up with the rapid increase
of resistant bacteria. This is causing common infections
to become untreatable and once again deadly (Matilla, et.
al. 2015).
An example of this is Staphylococcus aureus, a
gram-positive, round-shaped bacterial pathogen that
is responsible for many infections including bacteremia, pneumonia, sepsis, and wound and bloodstream
infections. It is quickly becoming resistant to more and
more forms of antibiotics which are making it increasingly difficult to cure. Methicillin-resistant staphylococcus
aureus (MRSA) is a group of S. aureus isolates resistant
to methicillin as well as many other kinds of antibiotics.
Vancomycin is one antibiotic that is used to treat MRSA
however vancomycin-resistant MRSA strains have started
to emerge (Jensen, et. al. 2015). The inability to effectively
treat MRSA has led to a resurgence in attempts to use
previously neglected antibacterial therapies to treat it.
This review is aimed at researching enzybiotics as one
alternative method to treating MRSA infections

Methods
This study was performed through the analysis of various
original and peer-reviewed articles which were accessed
from Touro’s online database including Proquest, PubMed,
and Plos One databases. The articles were critically read
analyzed and compared to determine the efficacy of enzybiotics as a possible treatment against multi-drug resistant MRSA.
What are Enzybiotics?
Enzybiotics fight bacterial infections through the use of
virus bacteriophages, viral derived lysins or antimicrobial
peptides. Some advantages enzybiotics have over regular antibiotics are their different mechanisms of killing
bacteria, including antibiotic-resistant bacteria. Most importantly, the use of certain enzybiotics has not resulted
in new development of bacterial resistance. For these
reasons, enzybiotics represent a promising alternative
to traditional antibiotic use by complimenting as well as
replacing antibiotics in treating bacterial pathogenic infections including MRSA.
Originally, Enzybiotics referred to designated bacteriophage enzymes provided with the ability to break down
cell walls which could be used as antimicrobial agents.
However, eventually, enzybiotics began referring to all
enzymes that displayed antibacterial or antifungal activity.
Bacteriophages
Bacteriophages are viruses that insert their genetic material into bacteria in order to replicate.The tails of phages
bind to receptors found on the surface of bacteria allowing
them to inject the DNA into the bacterial cell. For virulent phages, DNA replication produces many new phages
which burst from the host cell and kill it. These replicated
phages now move onto the next bacterial cell and repeat
the process (Thurber, 2009). Their characteristic of being
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able to replicate at the site of infection and therefore be
available in abundance where needed, gives bacteriophages
an advantage over traditional antibiotics (Gu, et. al. 2012).
Binding to a specific receptor is required for bacteriophages to infect bacteria, making phages extremely host-specific. Due to their narrow host range, using
phages to treat infections is advantageous, because phage
treatment can focus accurately on the pathogen infecting
human cells while not harming normal flora. For this reason, there are thought to be minimal side effects associated with phage therapy (Jensen, et. al. 2015).
Phage therapy has been used previously in the early
20th century, however, when antibiotics were discovered,
research in the phage treatment ended. Now that antibiotics are beginning to fail and there is a major need for
alternatives, phage therapy is being looked at as a possible option (Mattila, et. al. 2015). Although bacteria can
become resistant toward phages as well, phage therapy
can possibly be a greater option because of its ability to
change in response to the development of resistance by
target bacteria.
Nosocomial infections are infections that are contracted within a hospital environment. Transmission of
these infections often occurs via hospital equipment and
fomites that are not properly disinfected. This is a common way that MRSA infections get transmitted and is a
major concern amongst immunocompromised patients in
hospitals. Researchers have studied the ability of phages
to successfully decontaminate fomites associated with
nosocomial transmission. Glass coverslips were used to
represent decontamination of solid surfaces and cloth
from a lab coat to represent the coats worn by clinicians.
Strains of S. aureus were isolated from many sources
such as human nasal swabs, hospitals, dog hair, and poultry. Isolated phages were able to significantly reduce the
colony-forming units of MRSA from the surfaces of the
glass and fabric.They tended to demonstrate greater lytic
activity toward the MRSA strains isolated from human
sources. They were able to isolate at least six different
phages that displayed lytic activity against human MRSA
isolates and were able to decontaminate hard surfaces as
well as fabric surfaces (Jensen, et. al. 2015).
Phage Cocktails
Phage therapy isn’t infallible because bacteria have been
shown to develop resistance towards phages. In attempt
to solve this, the use of phage cocktails was studied. Phage
cocktails are when multiple phage types each possessing
different host ranges are combined. Studies have shown
that using this method delays the development of phage
resistant variants. However, it is difficult to acquire a set
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of phages that are effective against all variants of a specific
bacteria, and if too many different phages are used in effort to increase the host range the therapeutic efficiency
of the cocktail decreases.
Researchers have studied the possibility of creating
patient-specific phage cocktails containing phages specific for the infection present. Compared to pre-made
cocktails, this method of tailored phage cocktails ensures
that unnecessary phages aren’t used. For this method of
treatment to be possible, hospitals would be required to
have access to a large variety of phages at all times so that
when a pathogen is identified they can obtain the specific
phages that are effective against it.
The probability of successfully isolating phages effective
against common hospital-acquired bacterial infections on
demand was experimentally tested. Researchers found
that the probability of finding phages from sewage, an optimal resource of phages, varied greatly for different host
bacterium. Out of a total of 117 attempts, phages for only
a single strain of S. aureus were discovered. After continuing to investigate whether alternative sources would be
more suitable for obtaining phages effective against MRSA,
only phages for strain SA10 of S. aureus were found. This
specific study concluded that creating personalized phage
cocktails on demand is not possible for treating MRSA
like it is for other common infections. To treat these infections using this method, pre-made wide range cocktails
would have to be used. (Mattila, et. al. 2015).
Phages cocktails were also used to determine their potential synergistic ability to decontaminate fomites. The
difference is that the phages used weren’t required to be
extremely specific. Results of this study showed that the
cocktails were effective in decontaminating both the lab
coat fabric and the glass coverslips (Jensen, et. al. 2015).
Combination of Phage and Antibiotic Therapy
One way to use bacteriophages to combat infections is
to combine phage therapy with antibiotic therapy. The
combination of both antimicrobial agents seems to be
synergistic; the interactions between both antimicrobial
agents create a combined effect that is greater than than
each of their individual effects. Not only has using this
combination therapy shown to be helpful in effectively
controlling bacteria, but studies have shown that phage
therapy used along with antibiotics prevents the development of resistant strains. Therefore, using methods of
combined treatment of bacteriophages with antibiotics
can be effective in helping to resolve the issue of antibiotic resistance (Torres-Barceló, et. al. 2016).
S. aureus is one of the most common pathogens found
in diabetic foot infections. Overuse of antibiotics to treat
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these infections resulted in MRSA accounting for almost
half of the S. aureus isolates found in diabetic foot infections. It’s estimated that at least 50% of deaths caused by
diabetic foot infections are because of strains that were antibiotic resistant and therefore untreatable. One available
alternative treatment option is linezolid, an antibiotic that
is known to cure diabetic foot infections without causing
major side effects. Researchers have attempted to used
phage therapy along with linezolid to treat induced foot
infections in diabetic mice. To test their synergy, they used
phage MR 10 alone and in combination with linezolid.
Results of the study demonstrated that in a group of
mice that received an injection of phage MR 10, the infection was completely resolved after seven days. However,
greater results were observed in a group of mice that were
administered both phage MR 10 and linezolid. There, the
infection was also completely resolved by day seven but
there were comparatively lower bacterial loads on each
day when compared to treatment with phage 10 alone.This
showed that phage given along with linezolid were synergistic in controlling the pathogen population. Linezolid
prevented further growth of the pathogen because it is
a bacteriostatic antibiotic, and phage 10 killed the already
existing bacterial population (Chhibber et. al., 2013).
Endolysins
A major disadvantage to phage therapy is the ability of bacteria to develop resistance to the phages. Because of this,
researchers have looked into the possibility of purifying the
lysins from bacteriophages to be used separately as antimicrobial agents. Holin and lysin are two proteins that allow
reproduced phages to exit the infected bacterial host cell.
The holin creates pores in the cytoplasmic membrane and
allows the endolysin to access the peptidoglycan in the cell
wall of the bacteria.This causes water to flow into the cell,
resulting in its rupture, and release of the replicated phages.
Because of their properties endolysins are being studied as
possible antimicrobial agents that when applied to pathogenic gram-positive bacteria attack the peptidoglycan and
lyse the cell wall (Pastagia, et. al. 2013).
Cell walls of S. aureus are primarily composed of peptidoglycan, teichoic acids, and different surface proteins.
Peptidoglycan is a structural polymer that is composed
of glycan chains of repeating N-acetylglucosamine and
N-acetylmuramic acid that are cross-linked with peptide
side chains (Vacek, et. al. 2020). Peptidoglycan hydrolases
are often specific to certain species and genera since
their peptidoglycan structures vary. Consequently, the
use of phage endolysins as antimicrobials can help provide
a targeted therapeutic approach, without killing unrelated
commensal bacteria. It could also be useful in avoiding

the use of broad range antibiotics which often cause the
development of resistance (Becker, et. al. 2009).
LysK
Phage endolysins are found to have two or three domains.
One or two N-terminal catalytic domains and a C-terminal
cell wall binding domain. LysK is an endolysin derived from
staphylococcal bacteriophage K, a phage that has proven
to kill a broad range of pathogenic staphylococci. LysK is
characterized as an endopeptidase, an enzyme that breaks
peptide bonds. It contains three domains, two N-terminal
catalytic domains, cysteine, histidine-dependent amidohydrolase/peptidase (CHAP) domain, an amidase-2 domain,
and one c-terminal SH3B cell wall binding domain. LysK has
shown to have the ability to kill MRSA without permitting
bacterial resistance to develop.
In one specific study, researchers attempted to determine whether all three domains found on LysK were necessary for it to perform exolysis (lysis from outside the
cell). Analysis of their activity indicated that the CHAP
domain is sufficient for exolysis of S. aureus cells but it’s
activity was enhanced greatly when the SH3b domain was
present (Becker, et. al. 2009).
Researchers have cloned and expressed LysK in
Lactococcus lactis to test whether it can inhibit a range
of different staphylococci species including MRSA. Results
confirmed that the recombinant LysK had the ability to
degrade staphylococci cell walls. It was found to be active against a variety of live staphylococci, including MRSA
strains from Irish hospitals. Gram-positive bacterial strains
from other genera were not affected by the lysates containing LysK, suggesting that LysK is specific to staphylococcus.
These results suggest that LysK could have widespread
applications as a therapeutic agent against staphylococci
infections including MRSA (O’Flaherty, et. al. 2005).
CF-301
CF-301 is another example of a lysin that demonstrates
activity against S. aureus. In one particular study, CF-301’s
activity was examined alone and in combination with standard-of-care (SOC) antibiotics. It was tested in vitro against
laboratory and contemporary clinical strains of MRSA, and
in vivo against MRSA-induced murine bacteremia.
CF-301 killed S. Aureus rapidly both in vitro and in vivo.
Its rate of antimicrobial activity in vitro was found to be a
lot faster than that of the SOC antibiotics. CF-301 began
killing MRSA laboratory strains within 30 minutes in contrast to the antibiotics, which required six hours to reach
the same point. The same results were true when CF-301
was used to treat MRSA-induced mice. MRSA CFU (colony
forming unit) was tested in their blood prior to and post
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treatment.They found that after just 15 minutes there was
a large decrease in CFU and even more after an hour. This
rapid killing property of lysins makes them well suitable to
quickly reduce the bacterial load in infected hosts.
Aside from its activity alone, CF-301 exhibited synergy when combined with SOC antibiotics both in vitro
and in vivo. The synergy between the lysin and antibiotics
was assessed in three different ways. First with a timekill assay that studies the activity of antimicrobial agents
against bacteria over time. Two antibiotics, daptomycin,
and vancomycin were tested alone and in combination
with CF-301. Sub-MIC levels (minimal inhibitory concentration) of lysin demonstrated synergy with sub-MIC
levels of the two tested antibiotics. To confirm synergy, a
checkerboard assay was also used. When CF-301 treatment was combined with the two antibiotics it was more
effective at killing the majority of the tested MRSA strains
than when each treatment was used alone. A third method was used which further confirmed these findings by
showing that when in the presence of CF-301 the MIC
levels of the antibiotic majorly decreased.
Additionally, there was little to no resistance of S. aureus to CF-301 seen after treatment for 26 days, compared to high bacterial resistance of S. aureus to SOC
antibiotics which were 128 and 16 times the initial MIC.
When the two treatments were combined and MRSA
was treated with increasing concentrations of antibiotics in the presence of sub-MIC CF-301 for twenty-eight
days, there was only a 4- fold increase in their resistances.
These results demonstrate that the presence of the lysin
suppressed the formation of antibiotic resistance.
Mice with staphylococcal-induced bacteremia were
treated with CF-301 and daptomycin together and separately, in low and high challenge models. In some of the
studies, the lysin yielded a higher survival of the mice and
in others the antibiotics did, but, in all the cases the survival
rate yielded from the combination treatment significantly
outperformed the treatments with each of them alone.
These results can have clinical implications when designing new treatments using combinations of lysins and
antibiotics. Because CF-301 proved to act fast, it would
quickly reduce the burden of the pathogenic bacteria,
while the antibiotic would act on the remaining bacteria. Additionally, when the bacteria are exposed to small
amounts of lysin, which break the bonds of peptidoglycan,
it causes the bacterial structure to become more permeable which allows for the antibiotic to penetrate more
easily (Schuch, et. al. 2014).
Endolysins and Biofilm Eradication
S. Aureus forms biofilms within infected tissue which help
20

them grow and survive in the presence of antibiotics and
the immune system. Biofilm infections tend to develop
in patients with prosthetic objects implanted into their
bodies. They are harder to treat than free-living bacteria,
and even more so biofilms of antibiotic-resistant pathogens such as MRSA (Chopra, et. al. 2015a). These biofilms
are difficult to destroy because of their altered metabolic
activity as well as the presence of an extracellular matrix
making them difficult to penetrate (Rani et al, 2007).
Researchers attempted to test the efficiency of phage
lysins in eradicating old and new biofilms formed by
MRSA, possessing or lacking ica-locus. Phage-borne endolysin MR-10 was tested alone and in conjunction with minocycline. First, both kinds of biofilms were treated with
endolysin MR-10 alone. They found that the optimum
concentrations for eradicating young ica-negative MRSA
biofilm was 18 g/ml, and for ica-positive MRSA biofilms,
36 g/ml. Here, the difference in intracellular adhesion
seemed to affect the optimum concentrations needed.
The effectiveness of any antimicrobial agent against
biofilms is largely determined by the age of the biofilm.
Young biofilm formed by ica-negative and positive MRSA
can be controlled by using the antibiotic minocycline
alone at high concentrations, however, once the biofilm
gets older the minocycline becomes ineffective (Chopra,
et. al. 2015b). Since any lysin concentration was ineffective
against completely eradicating mature biofilm, minocycline was used at its highest concentrations together with
endolysin MR-10, in an attempt to completely eradicate
the biofilm. No significant decreases were observed when
equal concentrations of endolysin MR-10 and minocycline were used. The researchers believe the reason for
this is because both agents worked together on the top
layers of the biofilm and did not reach the interior. It is
known that antibiotics are unable to penetrate deep into
biofilms because of their complex matrix structure, and
since lysins are one-use enzymes it’s possible that both
agents bound to the same cells resulting in little activity
against them.
To test this theory, the researchers studied if sequential
treatment of both page endolysin MR-10 and minocycline
would have positive results in eliminating older MRSA
biofilm. Two sequences were studied and each had different results. First, they exposed the biofilm to endolysin
MR-10 for six hours and then treated it overnight with
minocycline. A decrease in mature biofilm was observed
to some extent after being treated using this method.
However, when the biofilm was first treated which minocycline for three hours followed by endolysin MR-10
overnight there was a more significant decrease in cell
count of the mature biofilm.
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The reasons for these results are as follows. Antibiotic
can not penetrate the layers of the biofilm and is only
effective against the active cells so when the antibiotic
was used first it was able to kill the metabolically active
cells which are found at upper layers if the biofilm. Since
endolysins are effective against bacteria regardless of
their metabolic activity and have low molecular weights,
endolysin MR-10 was able to penetrate more effectively
into the deeper layers of the biofilm which the antibiotics
could not reach. This study provides important research
that lysins have the potential as an antimicrobial agents in
the eradication of MRSA biofilm. Its mode of action targets the bacteria peptidoglycan and does not require the
bacterial cells to be metabolically active which is unlike
antibiotics (Chopra, et. al. 2015b).
Truncated and Chimeric Endolysins
Because endolysins have modular structures, domains can
be swapped or removed to create newly combined lysins
that have altered catalytic activities and binding specificity.
Doing so can optimize different properties lysins have
and eliminate possible downsides such as low solubility
and poor expression in heterologous hosts.
CHAPk is a truncated single domain lysin that has been
used experimentally to eliminate S. aureus from the nostrils
of artificially infected mice. It demonstrated high solubility,
rapid lytic activity, and high specificity against S. aureus. A
single treatment with CHAPk greatly reduced the bacteria
after just one hour. Using this enzyme may be an effective
way to eliminate MRSA colonization in the human nares.
The human nostril is the most frequent carriage site
of S. aureus which often serves as a reservoir for the
spread of the pathogen. It had been found to play a vital
role in the development of S. aureus infections, particularly in immunocompromised patients. Because CHAPk
has the potential to quickly reduce the reservoir, it can be
valuable in the prevention and spread of life-threatening
MRSA infections. This is a property that is not found in
antibiotic topical treatments which often take a couple of
days to effectively remove S. aureus (Fenton, et. al. 2010).
In a different study, the catalytic domains of two highly
soluble E. faecalis phage endolysins were fused with the
c-terminal cell wall binding domain of the staphylococcal
phage endolysin, Lys87. Two different chimeric endolysins
were created in hopes to solve the problem of low solubility. The combined endolysins were able to efficiently
lyse 96% of the 143 S. aureus clinical isolates that were
tested. Included in the clinical isolates were strains of
MRSA that represented some of the most relevant MRSA
epidemic clones. The MRSA strains showed to be susceptible to both of the chimeric endolysins.

Aside from showing activity against Staphylococcus, the
combined endolysins showed a broadened lytic activity towards enterococcus as well. This demonstrates that engineering chimeric endolysins can be a good way of obtaining
soluble and highly effective peptidoglycan hydrolyses that
have a broad lytic spectrum (Fernandes, et. al. 2012).
Bacteriocins
Bacteriocins are antibacterial proteins produced by
non-pathogenic bacteria that inhibit the growth of closely
related bacterial strains (Farkas-Himsley, 1980).They have
relatively narrow spectra of antimicrobial activity due to
being directed primarily toward bacterial strains closely
related to their producing strain. Bacteriocins make up a
family of proteins comprised of many different types, each
exhibiting different properties (Hanchi, et. al. 2017).
Lysostaphin
Lysostaphin is a bacteriocin that is secreted by
Staphylococcus simulans, a gram-positive bacteria.
Lysostaphin possesses the ability to lyse a staphylococcus
bacterial cell by disrupting its peptidoglycan layer (Schindler,
Schuhardt, 1964). The major substrate for lysostaphin is
the pentaglycine interpeptide bridge (Bowder, et. al. 1965).
Since this is an obvious feature of the cell wall of S. aureus, lysostaphin can selectively target it, thereby killing the
bacteria. Lysostaphin cleaves the staphylococci cell wall
between two amino acids in the pentaglycine cross bridge.
By cleaving these amino acids the lysostaphin destabilizes
the bacterial cell wall causing a loss of osmotic equilibrium
which ruptures the cell (Zygmunt, et. al. 1972).
Purifying, as well as cloning the lysostaphin gene into
different expression systems has led to creating a highly
purified recombinant lysostaphin with high specific activity. The availability of this recombinant as a potential
antimicrobial agent against S. Aureus has become of interest as new methods are being researched to combat
bacterial resistance.
Durancin 61A is a bacteriocin produced by Enterococcus
durans which is also being studied as a possible treatment
against MRSA. It has been found to exhibit antibacterial
activity when tested in vitro (Hanchi, et. al. 2017).
Lysostaphin Antimicrobial Activity in Vivo
Multiple studies have researched the use of recombinant
lysostaphin in treating S. aureus. One experiment tested
its ability to treat S. aureus-induced infections in mice.
It was found that administering 5mg/kg of lysostaphin
once a day for three days successfully cleared their
kidney infections caused by MRSA and significantly reduced their liver and spleen infections.This demonstrates
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lysostaphin’s ability to penetrate tissue when administered intravenously. Compared to a higher dose treatment over one day, repeated administration of a lower
dose of lysostaphin was found to be more effective for
the treatment of S. aureus (Kokai-Kun, et. al. 2007).
S. aureus is a leading cause of bacterial keratitis which
can result in irreversible damage, e.g. a loss of visual acuity
or even complete blindness. Keratitis is normally treated
with a topical treatment of antibiotics, such as ciprofloxacin, however more and more MRSA strains have become
resistant to it. Lysostaphin was used experimentally to
treat bacterial keratitis in rabbits against vancomycin, an
antibiotic used to treat MRSA infections. Results demonstrate that lysostaphin is an effective treatment for experimental keratitis caused by S. aureus.
Minimal inhibitory concentrations of lysostaphin were
determined for multiple strains of MRSA and were found
to be many times lower than the MIC’s of vancomycin. In
addition, Lysostaphin successfully sterilized the rabbit corneas when treated early on in the infection, compared to
vancomycin which did not completely sterilize them.When
treated later on in infection, although lysostaphin did not
completely sterilize the corneas, it reduced the CFU (colony forming unit) per cornea more than the vancomycin
therapy did when used to treat early in the infection.
Just like endolysins, bacteriocins share the property
remaining effective regardless of the metabolic status of
the bacterial cells. They can kill both rapidly growing cells
as well as non-dividing cells. Through experimentation,
lysostaphin proved to be an effective therapy during the
late stages of the staphylococcal infection when there is
minimal bacterial replication. This gives bacteriocins an
advantage over most antibiotics to which this is an unusual characteristic.
Infected eyes that were treated were found to be free
of detectible pathological changes after being observed
for seven days. Lysostaphin did not cause any conjunctival inflammation or corneal edema as did vancomycin. However, further studies are needed to determine
whether there are any adverse effects caused by repeated uses of topical lysostaphin since it has the potential
to cause an immune response against itself. The availability of recombinant lysostaphin can help with this issue
(Dajcs, et. al. 2000).
Bacteriocin Combination Treatments
Studies have shown that there is a synergistic effect
between lysostaphin and antibiotics. When lysostaphin
was experimentally used with oxacillin to treat MRSA in
vivo it improved its efficiency and allowed for a lower
therapeutic dose to be used. Treatment with this method
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would also be beneficial in preventing the emergence of
S. aureus that is resistant to lysostaphin (Kokai-Kun, et.
al. 2007).
Researchers have also attempted to combine the treatment of lysostaphin with endolysin LysK. They did so by
combining enzymes consisting of both the catalytic domains of LysK and Lysostaphin to treat infections. An experiment that combined the two enzymes demonstrated
greater growth inhibition of MRSA then each enzyme
showed alone (Becker, et. al. 2009).
Synergy between durancin 61A and vancomycin was
observed in inhibition of growth of S. aureus ATCC
700699, a methicillin-resistant staphylococcus strain. By
combining the two, each of their MIC levels were reduced drastically (Hanchi, et. al. 2017).
Conclusion
As antibiotic resistance continues to become a more
prevalent medical concern, scientists are constantly searching for new effective antimicrobial therapies.
Research and experimentation suggest that enzybiotics
may serve as possible solutions for combating multi-drug
resistant bacteria and particularly for the treatment of
MRSA. Each area of enzybiotics provides different advantages over antibiotics, however possible downsides need
to be taken into account.
Phage lysins seem to be a favorable way of combating
MRSA infections. Their speed of bactericidal activity, low
probability of affecting normal flora, as well as the small
chances of bacterial resistance, gives endolysins an advantage over traditional antibiotics. Additionally, the use
of phage lysins incorporates all the positive aspects of
phage therapy without the negative possibility of creating
resistant mutations.
Utilizing combination treatments of enzybiotics along
with antibiotics is another effective method of combating
MRSA. When tested, combination treatments tended to
be synergistic and showed the greatest results for killing MRSA than when each therapy was used alone. Each
therapy provides its own mechanism of action, so when
used together, each provides its specific capability’s to effectively combat the bacterial infection.
Despite the growing potential of enzybiotics, further
research must be conducted as well as implementing enzybiotics into clinical trials in order to establish enzybiotics as a tried and true therapeutic option for combating
MRSA infections.
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